BIORESEARCH UPDATE NEWS LETTER #8 Patent of GRISLIN (SX-fraction) Registered in Canada Following Japan and the US as Therapeutic Agent for Polycystic Ovary Syndrome (PCOS) ~ A Breakthrough for Infertility Treatment that can help grow happy families~

April 4, 2013 – Japan


SX-fraction (called Grislin in Japan), a proprietary extract derived from Maitake Mushroom, has been patented in three countries.  Japan, the US and Canada, entitled, “A Glycoprotein with Anti-diabetic, Anti-hypertensive, Anti-obesity and Anti-hyperlipidemic effects.”  Its new patent against PCOS (Polycystic Ovary Syndrome) is now registered in the same three countries.

 PCOS is a leading cause of infertility, affecting 5-10 % of women of reproductive age and believed to be closely associated with insulin resistance or metabolic syndrome.  SX-fraction is known to help increase insulin sensitivity balancing out the endocrine system. As a consequence, PCOS patients taking SX-fraction report that they start ovulating periodically and even become pregnant naturally.  A number of such clinical cases have been reported already.  Also, PCOS patients often repeat miscarriage.  However, after taking SX-fraction, the risk for miscarriage is reduced.  Therefore, SX-fraction may be useful for those PCOS patients who have not achieved goals of conventional therapy.  It is also appreciated by patients as a safe and natural substance with no side effects or a risk for secondary disease.*

 SX-fraction is a proprietary Maitake extract originally developed for people with metabolic syndrome. Improvement of health markers including the body weight is often seen among the patients taking SX-fraction. This confirms the fact that controlling insulin resistance is one of the most essential factors of maintaining good health.  SX-fraction is not just a mushroom extract but also a substantial proprietary natural agent with accumulated scientific validation of several important health benefits. The registration of its patent in the three countries has strengthened its significance.

(*)   OHSS (Ovarian Hyperstimulation Syndrome) exhibits complications such as swollen ovaries, ascites or pleural effusion, a condition often caused by taking fertility drugs repeatedly.